Fig. 6: The protein levels of Nrf2, BDNF, and MeCP2 in the striatum of DLB patients and the working model for this study.
From: Regulation of BDNF transcription by Nrf2 and MeCP2 ameliorates MPTP-induced neurotoxicity
A, B Protein expression of Nrf2, MeCP2 and BDNF in the striatum from DLB patients (n = 10) and controls (n = 10). Representative immunoblots were shown from the two groups. Data are shown as mean ± SEM (n = 10). *P < 0.05, **P < 0.01 (Student t test: T = −2.138, P = 0.046 for Nrf2, T = −3.448, P = 0.003 for MeCP2, and T = 2.361, P = 0.030 for BDNF). C There was a positive correlation between BDNF levels and Nrf2 levels in the subjects (n = 10). Furthermore, there was a negative correlation between BDNF levels and MeCP2 levels in the subjects (n = 10). D MPP+ and MPTP inhibit Nrf2 and upregulate MeCP2 expressions, which leads to suppress BDNF transcription and promotes dopaminergic neurotoxicity. SFN and MeCP2-HDO induce BDNF transcription by activating Bdnf exon I promoter and Bdnf exon IV promoter, resulting in neuroprotective effects against PD pathogenesis.
